FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	DC	20549	

|--|

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average I	ourden								
hours per response	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Lenington Rachel				2. Issuer Name and Ticker or Trading Symbol Athira Pharma, Inc. [ATHA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner V Officer (give title Other (specify							
(Last)	(F IIRA PHAI	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/14/2024)	below)	COO A	below)	, ,			
18706 NORTH CREEK PARKWAY, SUITE 104				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	LL W	/A	98011								2	X Form filed by One Reporting Person Form filed by More than One Reporting Person				ing		
(City)	(S	tate)	(Zip)		R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							satisfy					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				2A. Deemed Execution Date if any (Month/Day/Yea		Code (Instr.				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amount	(A) ((D)	Price	Transacti (Instr. 3 a	tion(s)			,		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Transcription or Exercise (Month/Day/Year) if any		ransa Code (I	saction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)			ries g Security	8. Price of Derivative Security (Instr. 5)	ve derivativ y Securitie) Benefici Owned Followin Reporte	re (es li ally li g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				c	Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Stock Option (Right to Buy)	\$3.26	02/14/2024			A		300,000		(1)	0)2/13/2034	Common Stock	300,000	\$0	300,00	00	D	

Explanation of Responses:

1. Shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.

/s/ Mark Worthington,

Attorney-in-Fact for Rachel

02/16/2024

Lenington

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.